Ashtta Lakshmi, A (2022) Phase II Non-Randomized Open Clinical Evaluation of Siddha Medicine “Megari Choornam” for Madhumegam (Diabetes Mellitus Type II). Masters thesis, Government Siddha Medical College, Chennai.
|
Text
3201 015 22 321911102 Ashtta Lakshmi A.pdf Download (18MB) | Preview |
Abstract
The clinical study on Madhumegam was carried out in the Post Graduate Department of Maruthuvam, Govt. Siddha Medical College, Arignar Anna Hospital, Chennai-106, during the period of 2019 - 2022. A total of 40 patients were treated in the Out Patient Department (OPD). The clinical and pathological assessment was carried out on the basis of both Siddha and Modern aspects. All the 40 patients were treated with Megari Chooranam, 800-1000mg BD with lukewarm water for 30 days. The responses were assessed once in 7 days for all the patients. • The toxicological study revealed no acute and sub-acute toxicity in study drug Megari Chooranam. • The pharmacological study of Megari Chooranam shows Anti-diabetic activity in STZ induced diabetic in Wister rats. • The peak incidence of Madhumegam was in the age group of 51- 60 yrs (45%) in both sexes. • The prevalence was higher among the lower income (47.5%). • The disease is more common in housewives (40%). So high incidence occurs in women. • Regarding diet, the disease is seen among mixed dietary habits of about 90%. • Regarding family history 82.5% had no relavent history. • All 40 patients were affected in Pitha kaalam (100%). • In Vatham Before treatment Abaanan (100%), Viyaanan (50%), Samaanan (100%), Kirukaran (100%), Devathathan (100%) were affected. After the treatment with study drug (80%) improvement seen in Abaanan, 85% improvement seen in Viyaanan, 80% improvement seen in Koorman, 90% improvement seen in Samaanan and Kirukaran, 85% improvement seen in Devathathan. CONCLUSION: Madhumegam is primarily due to derangement of Pitha kutram. The study medicine Megari Chooranam has Thuvarppu suvai thus it countervailed the deranged uyir thathukal and provided ease for all the patients with Madhumegam. The preclinical studies revealed no acute and sub-acute toxicity which proves that Megari Chooranam is safe for human administration. Further the pharmacological study shows that the trial drug Megari Chooranam possess significant anti-diabetic potential. No adverse effects of the trial drug were reported during the course of the study. Megari Chooranam significantly reduced blood sugar level and also reduced clinical features of Madhumegam. As the study drug is palatable and cost effective it can be utilized for huge population in public health sector. Based on all the pre-clinical and clinical evidences, the author concludes that the trial medicine Megari Chooranam is one of the best choice for treating Madhumegam (Diabetes Mellitus Type II). Further there is a scope for research on this trial drug if it is done on larger sample size with longer duration for the benefit of the society.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Reg.No.321911102 |
| Uncontrolled Keywords: | Phase II Non-Randomized Open Clinical Evaluation, Siddha Medicine, Megari Choornam, Madhumegam, Diabetes Mellitus Type II. |
| Subjects: | AYUSH > Maruthuvam |
| Depositing User: | Subramani R |
| Date Deposited: | 01 May 2023 05:41 |
| Last Modified: | 13 Feb 2024 05:28 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/21130 |
Actions (login required)
 |
View Item |
